Occupational Therapy for Medication Management in Low Vision

This study is exploring if occupational therapy (OT) interventions can help people with Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), or Glaucoma manage their medications better. These interventions include education on using additional task lighting, enhanced contrast, enlarged print instructions, smart apps, and organizational strategies. The researchers want to see if these strategies improve medication management skills, reduce errors, and help you use your remaining vision more effectively for this task. They will measure success by looking at your self-reported ability to perform daily activities and your medication management skills. The study aims to enroll 50 participants aged 50 to 100 years old, of all genders. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 50 participants. It is not specified if the study is randomized or blinded.
What's involved
You will receive a one-hour occupational therapy service and complete two assessment tools with the therapist. A follow-up interview will occur 4 weeks later.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up 4 weeks after the initial intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06593405

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

Recruiting
EARLY_PHASE1Ages 50+InterventionalTreatment
MCPHS University
~50 participants
Updated 2026-05-12 on ClinicalTrials.gov
What's tested:occupational therapy interventions for low vision care

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Revised Self Report Assessment of Functional Visual
Measured over Results from the Revised-Self-Report Assessment of Functional Visual Performance assessment will be determined on day 1 and 4 weeks later
+1 more outcome measured
Age-Related Macular Degeneration
1 sites across 1 states
Massachusetts1
  • Michelle Dowling, OTD · PRINCIPAL_INVESTIGATOR · MCPHS University

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clients with AMD, DR or Glaucoma
Clients who choose to participate will allow their deidentified data to be evaluated for outcomes.

Exclusion

Clients with other age related eye diseases other than AMD, DR or Glaucoma.
Clients who do not wish to participate in this study.
  • Revised Self Report Assessment of Functional VisualResults from the Revised-Self-Report Assessment of Functional Visual Performance assessment will be determined on day 1 and 4 weeks later

    A standardized assessment which provides information on how well adults with vision loss can perform daily tasks. This tool has 33 assessment components and a higher score indicates less functional impairment. A lower score indicates a higher impairment.

  • MediCog Screening ToolResults from the MediCog will be determined on day 1 and will be obtained 4 weeks later

    The Medi-Cog has a maximum score of 10 points, and a score of 7 or lower may indicate cognitive impairment.